"We are excited to recap an exceptional quarter for Xenon, where we made tremendous progress toward our goal of becoming a fully integrated neuroscience company" (President, CEO & Director Ian ...

WATERTOWN, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...

- All Sections of New Drug Application (NDA) Have Been Submitted to the FDA, Except Notification of Pre-Approval Inspection Readiness - -Manufacturer Has Requested Additional Time to Prepare for ...

, a biopharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, today announced that it believes it has successfully ...